A Gut-Restricted Liver X Receptor Agonist Ameliorates Liver Injury in Experimental Short Bowel Syndrome

Ayoung Kim; Daniel M. Alligood; Lingaiah Maram; Hannah M. Phelps; Michael D. Cameron; Jacob T. DeRousse; Jichang Han; Taylor J Dunning; Rachel L. Mintz; Alex Park; D R Lee; Deanna Davis; Christopher G. Huckstep; Rachael L. Field; Lamees Hegazy; Bernd H. Zinselmeyer; Jonathan R. Brestoff; Colin A. Martin; Brad W. Warner; Bahaa Elgendy; Gwendalyn J. Randolph

doi:10.1053/j.gastro.2025.12.015

Key Points

This research aims to evaluate the effects of a gut-restricted LXR agonist on liver injury in short bowel syndrome.
Administered gut-restricted LXR agonist WUSTL0717 in animal models of short bowel syndrome.
Assessed liver injury and metabolic health outcomes post-treatment.
WUSTL0717 reduced profibrotic liver injury in experimental models.
Treatment avoided systemic availability, indicating localized action in the intestine.

Implication

Experimental results show gut-restricted LXR agonist improves liver injury in short bowel syndrome, suggesting benefits for metabolic health.

Abstract

These data underscore the potential of gut-restricted LXR agonists to preserve metabolic health in the context of SBS. By acting locally in the intestine, WUSTL0717 positively mitigates profibrotic liver injury while avoiding systemic availability.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/69acc58f32b0ef16a404ff99 https://doi.org/10.1053/j.gastro.2025.12.015

View Full Paper

Ask AI

Bookmark

Share

A Gut-Restricted Liver X Receptor Agonist Ameliorates Liver Injury in Experimental Short Bowel Syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

A Gut-Restricted Liver X Receptor Agonist Ameliorates Liver Injury in Experimental Short Bowel Syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading